Aliases & Classifications for Personality Disorder

MalaCards integrated aliases for Personality Disorder:

Name: Personality Disorder 12 28 14
Personality Disorders 51 40 69
Character Disorder 12

Classifications:



External Ids:

Disease Ontology 12 DOID:1510
ICD9CM 34 301.8 301.89
ICD10 32 F60 F60.9

Summaries for Personality Disorder

MedlinePlus : 40 Personality disorders are a group of mental illnesses. They involve long-term patterns of thoughts and behaviors that are unhealthy and inflexible. The behaviors cause serious problems with relationships and work. People with personality disorders have trouble dealing with everyday stresses and problems. They often have stormy relationships with other people. The cause of personality disorders is unknown. However, genes and childhood experiences may play a role. The symptoms of each personality disorder are different. They can mild or severe. People with personality disorders may have trouble realizing that they have a problem. To them, their thoughts are normal, and they often blame others for their problems. They may try to get help because of their problems with relationships and work. Treatment usually includes talk therapy and sometimes medicine.

MalaCards based summary : Personality Disorder, also known as personality disorders, is related to schizoid personality disorder and obsessive-compulsive personality disorder, and has symptoms including pseudobulbar behavioral symptoms, restlessness and personality changes. An important gene associated with Personality Disorder is SLC6A4 (Solute Carrier Family 6 Member 4), and among its related pathways/superpathways are Peptide ligand-binding receptors and Transmission across Chemical Synapses. The drugs Fluvoxamine and Citalopram have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and cortex, and related phenotypes are shRNA abundance <= 50% and behavior/neurological

Disease Ontology : 12 A disease of mental health that involve long-term patterns of thoughts and behaviors that cause serious problems with relationships and work.

Wikipedia : 72 Personality disorders (PD) are a class of mental disorders characterized by enduring maladaptive... more...

Related Diseases for Personality Disorder

Diseases in the Personality Disorder family:

Multiple Personality Disorder

Diseases related to Personality Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 196)
# Related Disease Score Top Affiliating Genes
1 schizoid personality disorder 34.1 HTR1A HTR2A
2 obsessive-compulsive personality disorder 33.7 DRD3 SLC6A4
3 dependent personality disorder 33.5 DRD4 MAOA MAOB
4 antisocial personality disorder 32.5 ALDH2 COMT DRD2 MAOA MAOB SLC6A3
5 borderline personality disorder 31.9 BDNF COMT HTR1A HTR1B HTR2A HTR2C
6 social phobia 30.8 DRD2 MAOA SLC6A4
7 agoraphobia 30.5 HTR1A MAOA SLC6A4
8 alexithymia 30.3 COMT DRD2 HTR1A SLC6A4
9 impulse control disorder 30.2 DRD2 DRD3 DRD4
10 dysthymic disorder 30.1 HTR2A MAOA SLC6A4
11 kleptomania 29.9 HTR1A MAOA SLC6A4
12 bulimia nervosa 2 29.9 BDNF COMT HTR2A SLC6A4
13 alcohol use disorder 29.8 ALDH2 DRD2 SLC6A4
14 brain injury 29.7 BDNF COMT DRD2
15 conduct disorder 29.6 ALDH2 COMT DRD2 DRD4 MAOA SLC6A3
16 childhood-onset schizophrenia 29.6 COMT TPH1
17 cocaine abuse 29.6 DRD2 SLC6A3 SLC6A4
18 schizophreniform disorder 29.6 COMT DRD2
19 bulimia nervosa 1 29.5 BDNF COMT HTR1B HTR2A MAOA SLC6A4
20 chronic fatigue syndrome 29.5 COMT HTR1A MAOA SLC6A4 TPH2
21 postpartum depression 29.5 BDNF COMT HTR1A MAOA SLC6A4
22 traumatic brain injury 29.5 BDNF COMT DRD2
23 cocaine dependence 29.5 DRD2 DRD3 SLC6A3 SLC6A4
24 heroin dependence 29.4 BDNF DRD2 DRD4 SLC6A3
25 eating disorder 29.3 BDNF COMT DRD2 HTR2C SLC6A3 SLC6A4
26 drug dependence 29.2 BDNF DRD2 DRD3 SLC6A4
27 paranoid schizophrenia 29.0 BDNF COMT HTR2A MAOA SLC6A4 TPH2
28 opiate dependence 28.9 DRD2 DRD3 SLC6A4 TPH1
29 bipolar i disorder 28.9 BDNF COMT HTR1A HTR2A HTR2C SLC6A4
30 generalized anxiety disorder 28.8 BDNF DRD2 HTR1A HTR2A MAOA SLC6A4
31 delusional disorder 28.7 DRD2 DRD3 DRD4
32 post-traumatic stress disorder 28.5 BDNF COMT DRD2 HTR2A MAOA MAOB
33 panic disorder 28.4 BDNF COMT HTR1A HTR2A HTR2C MAOA
34 anxiety 28.4 BDNF COMT HTR1A HTR2A HTR2C MAOA
35 schizoaffective disorder 28.2 BDNF COMT DRD2 DRD3 HTR2A SLC6A4
36 substance dependence 28.0 BDNF DRD2 DRD3 DRD4 HTR1B MAOA
37 oppositional defiant disorder 28.0 COMT DRD2 DRD4 MAOA SLC6A3 SLC6A4
38 tobacco addiction 27.9 ALDH2 COMT DRD2 HTR2A MAOA SLC6A3
39 alcohol abuse 27.8 ALDH2 BDNF DRD2 DRD3 DRD4 SLC6A4
40 substance abuse 27.8 BDNF COMT DRD2 DRD3 DRD4 HTR1B
41 pathological gambling 27.3 DRD2 DRD3 DRD4 HTR2A MAOA MAOB
42 autism 26.4 BDNF COMT DRD2 DRD3 DRD4 HTR1A
43 mood disorder 26.4 BDNF COMT DRD2 DRD4 HTR1A HTR1B
44 bipolar disorder 26.2 BDNF COMT DRD2 DRD3 DRD4 HTR1A
45 disease of mental health 26.2 ALDH2 BDNF COMT DRD2 DRD3 DRD4
46 obsessive-compulsive disorder 26.0 BDNF COMT DRD2 DRD3 DRD4 HTR1A
47 major depressive disorder 25.7 BDNF COMT DRD2 DRD3 DRD4 HTR1A
48 schizophrenia 25.6 BDNF COMT DRD2 DRD3 DRD4 HTR1A
49 psychotic disorder 25.4 BDNF COMT DRD2 DRD3 DRD4 HTR1A
50 attention deficit-hyperactivity disorder 25.2 BDNF COMT DRD2 DRD3 DRD4 HTR1A

Comorbidity relations with Personality Disorder via Phenotypic Disease Network (PDN): (show all 14)


Acute Cystitis Alzheimer Disease
Anxiety Deficiency Anemia
Dependent Personality Disorder Dysthymic Disorder
Generalized Anxiety Disorder Heart Disease
Hypertension, Essential Hypothyroidism
Major Depressive Disorder Parkinson Disease, Late-Onset
Protein-Energy Malnutrition Schizophreniform Disorder

Graphical network of the top 20 diseases related to Personality Disorder:



Diseases related to Personality Disorder

Symptoms & Phenotypes for Personality Disorder

UMLS symptoms related to Personality Disorder:


pseudobulbar behavioral symptoms, restlessness, personality changes, photophobia, sleep disturbances

GenomeRNAi Phenotypes related to Personality Disorder according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 shRNA abundance <= 50% GR00343-S 9.28 ALDH2 COMT DRD2 DRD3 DRD4 HTR1A

MGI Mouse Phenotypes related to Personality Disorder:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.36 TPH2 MAOB SLC6A3 SLC6A4 TPH1 MAOA
2 homeostasis/metabolism MP:0005376 10.17 MAOA TPH2 MAOB SLC6A3 SLC6A4 TPH1
3 cardiovascular system MP:0005385 10.09 MAOA TPH2 SLC6A4 TPH1 DRD3 HTR1A
4 growth/size/body region MP:0005378 10.07 TPH2 SLC6A3 SLC6A4 HTR2C TPH1 DRD2
5 endocrine/exocrine gland MP:0005379 10.01 SLC6A3 SLC6A4 DRD2 ALDH2 BDNF HTR1B
6 adipose tissue MP:0005375 9.95 TPH2 TPH1 HTR2C DRD3 HTR1B DRD2
7 integument MP:0010771 9.86 TPH2 SLC6A3 SLC6A4 TPH1 ALDH2 BDNF
8 nervous system MP:0003631 9.77 TPH2 MAOB SLC6A3 SLC6A4 MAOA DRD3
9 muscle MP:0005369 9.7 SLC6A3 SLC6A4 TPH1 HTR2C HTR1B HTR2A
10 taste/olfaction MP:0005394 8.92 TPH2 SLC6A3 BDNF DRD2

Drugs & Therapeutics for Personality Disorder

Drugs for Personality Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 248)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fluvoxamine Approved, Investigational Phase 4,Phase 3 54739-18-3 5324346 3404
2
Citalopram Approved Phase 4,Phase 3,Phase 2 59729-33-8 2771
3
Topiramate Approved Phase 4,Phase 3 97240-79-4 5284627
4
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 51-61-6, 62-31-7 681
5
Risperidone Approved, Investigational Phase 4,Phase 1,Phase 2 106266-06-2 5073
6
Methylphenidate Approved, Investigational Phase 4 20748-11-2, 113-45-1 4158
7
Cycloserine Approved Phase 4,Phase 3,Phase 2 68-41-7 6234 401
8
Clomipramine Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2 303-49-1 2801
9
Guanfacine Approved, Investigational Phase 4,Phase 2 29110-47-2 3519
10
Lamotrigine Approved, Investigational Phase 4,Phase 2 84057-84-1 3878
11
Fluoxetine Approved, Vet_approved Phase 4,Phase 3,Phase 2 54910-89-3 3386
12
Ondansetron Approved Phase 4,Phase 2 99614-02-5 4595
13
Olanzapine Approved, Investigational Phase 4,Phase 3 132539-06-1 4585
14
Paroxetine Approved, Investigational Phase 4,Phase 3 61869-08-7 43815
15
Sertraline Approved Phase 4,Phase 3,Phase 2 79617-96-2 68617
16
Norepinephrine Approved Phase 4,Phase 3 51-41-2 439260
17
Haloperidol Approved Phase 4 52-86-8 3559
18
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613 2171
19
Ethanol Approved Phase 4,Phase 3,Phase 2 64-17-5 702
20
Propranolol Approved, Investigational Phase 4 525-66-6 4946
21
Pregabalin Approved, Illicit, Investigational Phase 4 148553-50-8 5486971
22
Naratriptan Approved, Investigational Phase 4 143388-64-1, 121679-13-8 4440
23
Sumatriptan Approved, Investigational Phase 4 103628-46-2 5358
24
Maleic acid Experimental Phase 4,Phase 3 110-16-7 444266
25 Anti-Anxiety Agents Phase 4,Phase 3,Phase 2,Phase 1
26 Antidepressive Agents Phase 4,Phase 3,Phase 2,Phase 1
27 Antidepressive Agents, Second-Generation Phase 4,Phase 3,Phase 2,Phase 1
28 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Phase 1
29 Cytochrome P-450 CYP1A2 Inhibitors Phase 4,Phase 3
30 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 3,Phase 2
31 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
32 Neurotransmitter Uptake Inhibitors Phase 4,Phase 3,Phase 2
33 Psychotropic Drugs Phase 4,Phase 3,Phase 2,Phase 1
34
Serotonin Phase 4,Phase 3,Phase 2,Phase 1 50-67-9 5202
35 Serotonin Agents Phase 4,Phase 3,Phase 2,Phase 1
36 Serotonin Uptake Inhibitors Phase 4,Phase 3,Phase 2
37 Tranquilizing Agents Phase 4,Phase 3,Phase 2,Phase 1
38 Antiparkinson Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
39 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1
40 Cholinergic Agents Phase 4,Phase 3,Phase 2
41 Cholinergic Antagonists Phase 4,Phase 3,Phase 2
42 Muscarinic Antagonists Phase 4,Phase 3,Phase 2
43 Parasympatholytics Phase 4,Phase 3,Phase 2
44 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
45 Anticonvulsants Phase 4,Phase 3,Phase 2
46 Anti-Obesity Agents Phase 4,Phase 3
47 Neuroprotective Agents Phase 4,Phase 3,Phase 2
48 Protective Agents Phase 4,Phase 3,Phase 2,Phase 1
49 Antipsychotic Agents Phase 4,Phase 3,Phase 2,Phase 1
50 Dopamine Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 567)

# Name Status NCT ID Phase Drugs
1 Efficacy of Omega-3 Fatty Acids on Borderline Personality Disorder Unknown status NCT00437099 Phase 4 Omacor®;Placebo
2 Cost-Effectiveness of Adding Web-Based Cognitive-Behavioral Therapy (CBT) to Luvox CR for Obsessive Compulsive Disorder (OCD) Unknown status NCT00743834 Phase 4 Luvox CR
3 Treatment Youth With Obsessive-Compulsive Disorder Unknown status NCT00708240 Phase 4 Escitalopram
4 Topiramate Augmentation in the Treatment of Obsessive-Compulsive Disorder Unknown status NCT00211744 Phase 4 topiramate
5 Reduction of Cardiovascular Risk in Severe Mental Illness Unknown status NCT01182012 Phase 4
6 Study of Lamotrigine Treatment of Affective Instability in Borderline Personality Disorder Completed NCT00634062 Phase 4 Lamotrigine;Placebo
7 Treating Suicidal Behavior and Self-Mutilation in People With Borderline Personality Disorder Completed NCT00533117 Phase 4 Fluoxetine
8 Effective Measurement of Risperidone Treatment Outcome for Persons With Borderline Personality Disorder Completed NCT00204347 Phase 4 risperidone
9 Comparing Treatments for Self-Injury and Suicidal Behavior in People With Borderline Personality Disorder Completed NCT00834834 Phase 4 Fluoxetine;Citalopram
10 Effects of Comorbid Personality Disorder on the Treatment of Bipolar I Disorder Completed NCT00178061 Phase 4
11 Methylphenidate Hydrochloride Controlled-Release Tablets Augmentation Strategy for Patients With Obsessive Compulsive Disorder Completed NCT02194075 Phase 4 Fluvoxamine+Methylphenidate hydrochloride;Fluvoxamine+sugar pill
12 D-Cycloserine as an Adjunct to Internet-CBT for OCD Completed NCT01649895 Phase 4 D-Cycloserine;Placebo
13 Ondansetron Augmentation in Treatment-resistant OCD Completed NCT01303536 Phase 4 Ondansetron
14 Augmentation in Tx-resistant OCD: an Open Label Trial Completed NCT00590642 Phase 4
15 Deep Brain Stimulation for Obsessive Compulsive Disorder (OCD PMCF) Completed NCT01135745 Phase 4
16 Effectiveness and Safety of Atypical Antipsychotic Agents in Augmenting SSRI-Refractory Obsessive-Compulsive Disorder Completed NCT00854919 Phase 4 atypical antipsychotic drug
17 Ondansetron in Treatment Resistant Obsessive Compulsive Disorder (OCD) Completed NCT00796497 Phase 4 ondansetron
18 Comparison of Effects Between Conventional Dose and High Dose Escitalopram on Clinical Improvement in Patients With Obsessive-compulsive Disorder Completed NCT00723060 Phase 4 escitalopram
19 Group Cognitive Behavioral Therapy Versus Fluoxetine for Obsessive-Compulsive Disorder: a Practical Trial Completed NCT00680602 Phase 4 SSRI (fluoxetine, sertraline, paroxetine, citalopram)
20 Quetiapine Augmentation Versus Clomipramine Augmentation of SSRI for Obsessive-compulsive Disorder Patients Completed NCT00564564 Phase 4 Quetiapine;Clomipramine
21 Using Drug Augmentation to Treat Obsessive Compulsive Disorder Patients Who Did Not Respond to Previous Treatment Completed NCT00466609 Phase 4 Clomipramine (fluoxetine plus clomipramine);Quetiapine (fluoxetine plus quetiapine);Placebo (fluoxetine plus placebo)
22 Duloxetine for the Treatment of Obsessive Compulsive Disorder (OCD) Completed NCT00464698 Phase 4 Duloxetine
23 Effectiveness of Sertraline and Cognitive Behavioral Therapy in Treating Pediatric Obsessive-Compulsive Disorder Completed NCT00382291 Phase 4 Regular Titration;Placebo;Slow Titration
24 Escitalopram for the Treatment of Obsessive Compulsive Disorder (OCD) Completed NCT00116532 Phase 4 Escitalopram
25 Treatment of Obsessive-Compulsive Disorder Completed NCT00000373 Phase 4 olanzapine + fluoxetine;placebo + fluoxetine
26 Antidepressant Safety in Kids Study Completed NCT00395213 Phase 4 Selective serotonin reuptake inhibitor (SSRI) and serotonin-norepinephrine reuptake inhibitor (SNRI) medications
27 Multimodal Treatment Study of Children With Attention Deficit and Hyperactivity Disorder (MTA) Completed NCT00000388 Phase 4 Anti-ADHD medication
28 Amoxicillin for the Treatment of Pediatric Autoimmune Disorders Associated With Streptococcal Infections Completed NCT00001658 Phase 4 Amoxicillin
29 Trial of Seroquel SR for Alcohol Dependence and Comorbid Anxiety Completed NCT00352469 Phase 4 Seroquel XR
30 Treatment Trial for Psychogenic Nonepileptic Seizures Completed NCT00835627 Phase 4 sertraline
31 Treatments for Psychogenic Nonepileptic Seizures (NES) Completed NCT00159965 Phase 4 sertraline;placebo
32 Fear Conditioned Response in Healthy Subjects and in OCD Patients Pre and Post Treatment With Sertraline. Recruiting NCT03068429 Phase 4 Sertraline Hydrochloride
33 Brief Intervention for OCD Fears Recruiting NCT02790710 Phase 4 Propanolol;Placebo
34 Probiotic Treatment in Adult Obsessive-Compulsive Disorder Recruiting NCT02334644 Phase 4
35 A Study of Pregabalin (Lyrica) Augmentation in Serotonin Reuptake Inhibitor-Refractory Obsessive Compulsive Disorder Recruiting NCT00994786 Phase 4 pregabalin;Placebo
36 Efficacy of Adding Topiramate to Current Treatment in Refractory Obsessive Compulsive Disorder (OCD) Recruiting NCT00182520 Phase 4 Topiramate;placebo
37 Efficacy of Exposure and Response Prevention(ERP) and SSRIs in Chinese OCD Patients Recruiting NCT02022709 Phase 4 Fluoxetine;Sertraline;Paroxetine;Citalopram;Fluvoxamine
38 Effects of Ondansetron in Obsessive-compulsive and Tic Disorders Recruiting NCT03239210 Phase 4 Ondansetron;Placebo
39 Translational Approach to the Understanding and Treatment of Obsessive-Compulsive Disorder (OCD). Can D-Cycloserine Enhance and Stabilize the Treatment-response in Relapsed and Non-responding OCD-patients? Active, not recruiting NCT02656342 Phase 4 D-Cycloserine;Placebo
40 Sertraline in Generalized Social Phobia With Co-Occurring Anxiety and Mood Disorders Active, not recruiting NCT00182533 Phase 4 Sertraline;Placebo
41 Pharmacology of Cognition in Schizotypal Personality Disorder Terminated NCT00353379 Phase 4 Guanfacine;Placebo
42 Efficacy of a Triptan in the Treatment of Hostility and Aggression Among Convicts With a Psychiatric Treatment Order Terminated NCT00282165 Phase 4 naratriptan;placebo
43 Fluvoxamine Maleate in the Treatment of Obsessive-Compulsive Disorder: A Post-marketing Clinical Study in Children and Adolescents Terminated NCT00352768 Phase 4 Fluvoxamine maleate;Placebo
44 Fluoxetine for Obsessive-Compulsive Disorder in Children and Adolescents With Bipolar Disorder Terminated NCT00592852 Phase 4 fluoxetine
45 Cipralex in Treatment of Depressive Symptoms and Chronic Back Pain Withdrawn NCT00227292 Phase 4 Escitalopram;Placebo
46 BOSCOT : A Randomised Controlled Trial of Cognitive Behavioural Therapy in Borderline Personality Disorder Completed NCT00538135 Phase 3
47 Seroquel Extended Release (XR) for the Management of Borderline Personality Disorder (BPD) Completed NCT00880919 Phase 3 quetiapine extended-release;Placebo
48 Clinical Research Study to Evaluate Selegiline in the Treatment of Borderline Personality Disorder Completed NCT01912391 Phase 3 Selegiline;Placebo (for Selegiline)
49 Quetiapine Treatment for Symptoms Associated With Borderline Personality Disorder Completed NCT00122070 Phase 3 Quetiapine Fumarate
50 Olanzapine in Patients With Borderline Personality Disorder Completed NCT00091650 Phase 3 Olanzapine;placebo

Search NIH Clinical Center for Personality Disorder

Genetic Tests for Personality Disorder

Genetic tests related to Personality Disorder:

# Genetic test Affiliating Genes
1 Personality Disorder 28

Anatomical Context for Personality Disorder

MalaCards organs/tissues related to Personality Disorder:

38
Brain, Testes, Cortex, Prefrontal Cortex, Liver, Amygdala, Eye

Publications for Personality Disorder

Articles related to Personality Disorder:

(show top 50) (show all 2151)
# Title Authors Year
1
Enhanced mental imagery and intact perceptual organization in schizotypal personality disorder. ( 29131991 )
2018
2
The effects of working memory load and attention refocusing on delay discounting rates in alcohol use disorder with comorbid antisocial personality disorder. ( 29277285 )
2018
3
Improving functional outcomes in women with borderline personality disorder and PTSD by changing PTSD severity and post-traumatic cognitions. ( 29448136 )
2018
4
The rewarding nature of provocation-focused rumination in women with borderline personality disorder: a preliminary fMRI investigation. ( 29372058 )
2018
5
Behavioural mimicry and loneliness in borderline personality disorder. ( 29407356 )
2018
6
Treating borderline personality disorder with oxytocin: An enthusiastic note of caution. Commentary to Servan et al. The effect of oxytocin in borderline personality disorder. ( 29402386 )
2018
7
Psychosocial stress differentially affects emotional empathy in women with borderline personality disorder and healthy controls. ( 29417987 )
2018
8
Episodic memory and consciousness in antisocial personality disorder and conduct disorder. ( 29353574 )
2018
9
Transient hallucinations during interpersonal stress in an adolescent with borderline personality disorder. ( 29374970 )
2018
10
Reduced white matter integrity in borderline personality disorder: A diffusion tensor imaging study. ( 28922736 )
2018
11
Book Review: Integrated Modular Treatment for Borderline Personality Disorder: A Practical Guide to Combining Effective Treatment Methods Integrated Modular Treatment for Borderline Personality Disorder: A Practical Guide to Combining Effective Treatment Methods . Livesley W. John . Cambridge (UK) : Cambridge University Press ; 2017 . 297 p. US$66.50 . Paperback. ISBN 978-1-10-67974-0 . Reviewer rating: Excellent. ( 29433334 )
2018
12
Avoidant personality disorder and social phobia: Does mindreading make the difference? ( 29096207 )
2018
13
Continuity between DSM-5 Section II and Section III personality traits for obsessive-compulsive personality disorder. ( 29024130 )
2018
14
Alliance Rupture and Resolution in Dialectical Behavior Therapy for Borderline Personality Disorder. ( 29388901 )
2018
15
Mentalization-Based Treatment for Concurrent Borderline Personality Disorder and Substance Use Disorder: A Randomized Controlled Feasibility Study. ( 29402870 )
2018
16
Change in Biased Thinking in a Treatment Based on the Motive-Oriented Therapeutic Relationship for Borderline Personality Disorder. ( 29388899 )
2018
17
Quasi-psychosis in covert Narcissistic Personality Disorder-A case report. ( 29272784 )
2018
18
The Role of Negative Affect and Self-Concept Clarity in Predicting Self-Injurious Urges in Borderline Personality Disorder Using Ecological Momentary Assessment. ( 29388895 )
2018
19
Features of borderline personality disorder as a mediator of the relation between childhood traumatic experiences and psychosis-like experiences in patients with mood disorder. ( 29353179 )
2018
20
Attachment-Related Regulatory Processes Moderate the Impact of Adverse Childhood Experiences on Stress Reaction in Borderline Personality Disorder. ( 29388902 )
2018
21
Opioid addiction and borderline personality disorder. ( 29283477 )
2018
22
Variability in phase and amplitude of diurnal rhythms is related to variation of mood in bipolar and borderline personality disorder. ( 29374207 )
2018
23
Clinical Components of Borderline Personality Disorder and Personality Functioning. ( 29393279 )
2018
24
Differential relations of executive functioning to borderline personality disorder presentations in adolescents. ( 29388349 )
2018
25
Shining lights in dark corners of people's lives: Reaching consensus for people with complex mental health difficulties who are given a diagnosis of personality disorder. ( 29417661 )
2018
26
Assessing advanced theory of mind and alexithymia in patients suffering from enduring borderline personality disorder. ( 29360051 )
2018
27
Borderline personality disorder and sexual abuse: A systematic review. ( 29407572 )
2018
28
Affect dysregulation, psychoform dissociation, and adult relational fears mediate the relationship between childhood trauma and complex posttraumatic stress disorder independent of the symptoms of borderline personality disorder. ( 29410773 )
2018
29
Stability of the Pregnancy Obsessive-Compulsive Personality Disorder Symptoms Checklist. ( 29067550 )
2018
30
On the potential for iatrogenic effects of psychiatric crisis services: The example of dialectical behavior therapy for adult women with borderline personality disorder. ( 29369662 )
2018
31
Fear of Being Laughed at in Borderline Personality Disorder. ( 29410640 )
2018
32
Predictive Utility of Personality Disorder in Depression: Comparison of Outcomes and Taxonomic Approach. ( 28926307 )
2017
33
Clinician Ratings of Vulnerable and Grandiose Narcissistic Features: Implications for an Expanded Narcissistic Personality Disorder Diagnosis. ( 29215903 )
2017
34
Predicting Nonsuicidal Self-Injury in Borderline Personality Disorder Using Ecological Momentary Assessment. ( 28072044 )
2017
35
The Relationship between Survival Sex and Borderline Personality Disorder Symptoms in a High Risk Female Population. ( 28885558 )
2017
36
What is the effect on comorbid personality disorder of brief panic-focused psychotherapy in patients with panic disorder? ( 29212135 )
2017
37
Stability or instability in avoidant personality disorder:Mode fluctuations within schema therapy sessions. ( 28527713 )
2017
38
The Reality of Recovery in Personality Disorder, By Heather Castillo. ( 28084097 )
2017
39
The specificity of emotion dysregulation in adolescents with borderline personality disorder: comparison with psychiatric and healthy controls. ( 28078089 )
2017
40
People with Borderline Personality Disorder and Burns: Some Considerations for Health Professionals. ( 28945490 )
2017
41
Association of monoamine oxidase-A genetic variants and amygdala morphology in violent offenders with antisocial personality disorder and high psychopathic traits. ( 28851912 )
2017
42
Antisocial Personality Disorder in Older Adults: A Critical Review. ( 28954596 )
2017
43
Neuropsychology and emotion processing in violent individuals with antisocial personality disorder or schizophrenia: The same or different? A systematic review and meta-analysis. ( 28992741 )
2017
44
Compelled to Risk: Does Sexual Compulsivity Explain the Connection Between Borderline Personality Disorder Features and Number of Sexual Partners? ( 28072043 )
2017
45
Neurocognitive dysfunction in problem gamblers with co-occurring antisocial personality disorder. ( 28528231 )
2017
46
Estimating the prevalence of borderline personality disorder in mothers involved in youth protection services. ( 28944592 )
2017
47
Narcissistic Personality Disorder and suicidal behavior in mood disorders. ( 27816770 )
2017
48
Oxytocin improves facial emotion recognition in young adults with antisocial personality disorder. ( 28865940 )
2017
49
Altered Empathy for Psychological and Physical Pain in Borderline Personality Disorder. ( 28072040 )
2017
50
Cognitive behavioral therapy for posttraumatic stress disorder in individuals with severe mental illness and borderline personality disorder. ( 28086181 )
2017

Variations for Personality Disorder

Expression for Personality Disorder

Search GEO for disease gene expression data for Personality Disorder.

Pathways for Personality Disorder

Pathways related to Personality Disorder according to GeneCards Suite gene sharing:

(show all 26)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.44 DRD2 DRD3 DRD4 HTR1A HTR1B HTR2A
2
Show member pathways
12.86 ALDH2 COMT MAOA SLC6A3 SLC6A4
3
Show member pathways
12.65 COMT DRD2 DRD3 DRD4 MAOA MAOB
4 12.44 COMT HTR1A TPH1 TPH2
6
Show member pathways
12.17 BDNF DRD2 HTR1A HTR1B
7
Show member pathways
12.14 ALDH2 MAOA MAOB TPH1 TPH2
8 12.08 BDNF HTR1A HTR2A MAOA SLC6A4 TPH1
9
Show member pathways
11.92 BDNF DRD2 MAOA MAOB SLC6A3
10 11.78 DRD3 DRD4 HTR2A
11
Show member pathways
11.78 DRD2 DRD3 DRD4
12
Show member pathways
11.76 DRD2 DRD3 DRD4 HTR1A HTR1B HTR2A
13 11.7 DRD2 HTR2A HTR2C
14 11.66 HTR1A HTR1B HTR2A HTR2C MAOA MAOB
15
Show member pathways
11.63 COMT MAOA MAOB
16
Show member pathways
11.49 ALDH2 MAOA MAOB
17
Show member pathways
11.41 MAOA SLC6A3 SLC6A4 TPH2
18
Show member pathways
11.26 ALDH2 MAOA MAOB
19
Show member pathways
11.07 ALDH2 COMT MAOA SLC6A3 SLC6A4
20
Show member pathways
11.05 COMT MAOA TPH1
21 10.97 DRD2 DRD3
22 10.92 HTR2A HTR2C
23 10.85 COMT MAOA MAOB
24
Show member pathways
10.85 ALDH2 COMT MAOA MAOB
25
Show member pathways
10.8 ALDH2 MAOA MAOB
26 10.67 HTR1A HTR1B HTR2A HTR2C MAOA SLC6A4

GO Terms for Personality Disorder

Cellular components related to Personality Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of membrane GO:0016021 9.73 COMT DRD2 DRD3 DRD4 HTR1A HTR1B
2 neuron projection GO:0043005 9.56 SLC6A3 SLC6A4 TPH1 TPH2
3 axon GO:0030424 9.46 COMT DRD2 HTR2A SLC6A3
4 integral component of plasma membrane GO:0005887 9.28 DRD2 DRD3 DRD4 HTR1A HTR1B HTR2A

Biological processes related to Personality Disorder according to GeneCards Suite gene sharing:

(show top 50) (show all 64)
# Name GO ID Score Top Affiliating Genes
1 cellular calcium ion homeostasis GO:0006874 9.91 DRD3 DRD4 HTR2A HTR2C
2 response to toxic substance GO:0009636 9.9 DRD2 MAOB SLC6A4
3 circadian rhythm GO:0007623 9.89 SLC6A4 TPH1 TPH2
4 locomotory behavior GO:0007626 9.89 DRD2 DRD3 HTR2C SLC6A3
5 response to ethanol GO:0045471 9.88 DRD2 DRD3 HTR1B MAOB SLC6A3
6 positive regulation of fat cell differentiation GO:0045600 9.87 HTR2A HTR2C TPH1
7 social behavior GO:0035176 9.86 DRD3 DRD4 SLC6A4
8 feeding behavior GO:0007631 9.85 DRD2 HTR1B HTR2C
9 release of sequestered calcium ion into cytosol GO:0051209 9.84 DRD2 HTR2A HTR2C
10 negative regulation of adenylate cyclase activity GO:0007194 9.82 DRD2 DRD3 DRD4
11 behavioral fear response GO:0001662 9.81 DRD4 HTR1A HTR2C
12 response to amphetamine GO:0001975 9.8 DRD2 DRD3 DRD4
13 arachidonic acid secretion GO:0050482 9.79 DRD2 DRD3 DRD4
14 G-protein coupled serotonin receptor signaling pathway GO:0098664 9.78 HTR1A HTR1B HTR2A
15 dopamine receptor signaling pathway GO:0007212 9.77 DRD2 DRD3 DRD4
16 vasoconstriction GO:0042310 9.76 HTR1A HTR1B SLC6A4
17 response to cocaine GO:0042220 9.76 DRD2 DRD3 HTR1B SLC6A3
18 negative regulation of protein secretion GO:0050709 9.75 DRD2 DRD3 DRD4
19 negative regulation of synaptic transmission, glutamatergic GO:0051967 9.74 DRD2 HTR1B HTR2A
20 temperature homeostasis GO:0001659 9.73 DRD2 HTR2A
21 response to iron ion GO:0010039 9.73 DRD2 SLC6A3
22 synaptic transmission, dopaminergic GO:0001963 9.73 DRD2 DRD3
23 negative regulation of cAMP biosynthetic process GO:0030818 9.73 DRD4 HTR1B
24 positive regulation of kinase activity GO:0033674 9.73 DRD4 HTR2A
25 prepulse inhibition GO:0060134 9.73 DRD2 DRD3 SLC6A3
26 behavioral response to ethanol GO:0048149 9.72 DRD2 DRD4
27 bone remodeling GO:0046849 9.72 HTR1B TPH1
28 neurotransmitter biosynthetic process GO:0042136 9.72 SLC6A3 SLC6A4
29 negative regulation of voltage-gated calcium channel activity GO:1901386 9.72 DRD2 DRD4
30 G-protein coupled receptor internalization GO:0002031 9.72 DRD2 DRD3 HTR1B
31 ammonium transmembrane transport GO:0072488 9.71 SLC6A3 SLC6A4
32 positive regulation of renal sodium excretion GO:0035815 9.71 DRD2 DRD3
33 catecholamine metabolic process GO:0006584 9.71 COMT MAOA
34 adenohypophysis development GO:0021984 9.71 DRD2 SLC6A3
35 adenylate cyclase-inhibiting dopamine receptor signaling pathway GO:0007195 9.71 DRD2 DRD3 DRD4
36 regulation of dopamine secretion GO:0014059 9.71 DRD2 DRD3 HTR1B HTR2A
37 monoamine transport GO:0015844 9.7 SLC6A3 SLC6A4
38 aromatic amino acid family metabolic process GO:0009072 9.7 TPH1 TPH2
39 regulation of cAMP metabolic process GO:0030814 9.7 DRD2 DRD3
40 dopamine uptake involved in synaptic transmission GO:0051583 9.7 SLC6A3 SLC6A4
41 neurotransmitter catabolic process GO:0042135 9.7 COMT MAOA MAOB
42 regulation of hormone secretion GO:0046883 9.69 HTR1A HTR2A
43 regulation of dopamine metabolic process GO:0042053 9.69 DRD4 HTR1A SLC6A3
44 indolalkylamine biosynthetic process GO:0046219 9.68 TPH1 TPH2
45 regulation of dopamine uptake involved in synaptic transmission GO:0051584 9.68 DRD2 DRD3
46 negative regulation of serotonin secretion GO:0014063 9.67 HTR1B MAOB
47 positive regulation of phosphatidylinositol biosynthetic process GO:0010513 9.67 HTR2A HTR2C
48 adenylate cyclase-inhibiting serotonin receptor signaling pathway GO:0007198 9.67 HTR1A HTR1B
49 regulation of behavior GO:0050795 9.67 HTR1A HTR1B HTR2A
50 behavioral response to cocaine GO:0048148 9.67 DRD2 DRD3 DRD4 HTR2A

Molecular functions related to Personality Disorder according to GeneCards Suite gene sharing:

(show all 17)
# Name GO ID Score Top Affiliating Genes
1 oxidoreductase activity GO:0016491 9.96 ALDH2 MAOA MAOB TPH1 TPH2
2 signal transducer activity GO:0004871 9.91 DRD2 DRD3 DRD4 HTR1A HTR1B HTR2A
3 neurotransmitter receptor activity GO:0030594 9.62 HTR1A HTR1B HTR2A HTR2C
4 dopamine neurotransmitter receptor activity, coupled via Gi/Go GO:0001591 9.61 DRD2 DRD3 DRD4
5 dopamine neurotransmitter receptor activity GO:0004952 9.58 DRD2 DRD3 DRD4
6 neurotransmitter:sodium symporter activity GO:0005328 9.57 SLC6A3 SLC6A4
7 G-protein coupled serotonin receptor activity GO:0004993 9.56 HTR1A HTR1B HTR2A HTR2C
8 monoamine transmembrane transporter activity GO:0008504 9.55 SLC6A3 SLC6A4
9 primary amine oxidase activity GO:0008131 9.54 MAOA MAOB
10 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced pteridine as one donor, and incorporation of one atom of oxygen GO:0016714 9.52 TPH1 TPH2
11 dopamine:sodium symporter activity GO:0005330 9.51 SLC6A3 SLC6A4
12 1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding GO:0071886 9.49 HTR2A HTR2C
13 tryptophan 5-monooxygenase activity GO:0004510 9.48 TPH1 TPH2
14 dopamine binding GO:0035240 9.46 DRD2 DRD3 DRD4 SLC6A3
15 serotonin binding GO:0051378 9.26 HTR1A HTR1B HTR2A HTR2C
16 drug binding GO:0008144 9.17 DRD2 DRD3 DRD4 HTR1B HTR2A HTR2C
17 G-protein coupled receptor activity GO:0004930 10 DRD2 DRD3 DRD4 HTR1A HTR1B HTR2A

Sources for Personality Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....